During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...

Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment. The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

Pfizer Inc. (NYSE:PFE) will increase its dividend from last year's comparable payment on the 7th of March to $0.43. This will take the annual payment to 6.5% of the stock price, which is above ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...

Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a Standalone Total ...